SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 13, 2003
----------------
SONTRA MEDICAL CORPORATION
--------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Minnesota
------------------------------------------------
(State or Other Jurisdiction of Incorporation)
0 230-17 41-1644949
------------------------ ---------------------------------
(Commission File Number) (IRS Employer Identification No.)
58 Charles Street, Cambridge, Massachusetts 02141
----------------------------------------------- ---------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (617) 494-5337
--------------
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibits
99.1 Press Release issued by the Securities and Exchange Commission dated
January 13, 2003.
ITEM 9. REGULATION FD DISCLOSURE
On January 13, 2003, the Securities and Exchange Commission ("SEC") issued
cease-and-desist orders relating to an SEC Administrative Proceeding, Release
No. 34-47167, instituted against Anika Therapeutics, Inc. ("Anika"), the former
chief executive officer of Anika, and Sean F. Moran, the former chief financial
officer of Anika. In accordance with the final terms of the Order, Mr. Moran
agreed to cease and desist from committing or causing any violations and any
future violations of certain sections and rules promulgated under the Securities
Exchange Act of 1934. The SEC has not imposed any fines or additional penalties
on Mr. Moran in connection with this investigation. Mr. Moran currently serves
as the Chief Financial Officer of Sontra Medical Corporation. A copy of a press
release issued by the SEC is attached as Exhibit 99.1 to this Current Report on
Form 8-K.
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Sontra Medical Corporation
January 14, 2003 By: /s/ Thomas W. Davison
-----------------------------------
Thomas W. Davison
President and Chief Executive Officer
- 3 -
EXHIBIT INDEX
Exhibit
Number Description
- ------- -----------
99.1 Press Release issued by the Securities and Exchange Commission dated
January 13, 2003.
- 4 -